Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study (Diabetes Metab J 2021;45:675-83).
作者信息
Moon Jun Sung, Suh Sunghwan, Kim Sang Soo, Jin Heung Yong
机构信息
Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Korea.
Department of Internal Medicine, Dong-A University Medical Center, Dong-A University College of Medicine, Busan, Korea.
出版信息
Diabetes Metab J. 2022 Jan;46(1):162-163. doi: 10.4093/dmj.2021.0331. Epub 2022 Jan 27.
Abstract
摘要
相似文献
1
Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study (Diabetes Metab J 2021;45:675-83).四联口服降糖药治疗血糖控制不佳的2型糖尿病的疗效和安全性：一项多中心、回顾性、观察性研究（《糖尿病与代谢杂志》2021年；45:675 - 83）
Diabetes Metab J. 2022 Jan;46(1):162-163. doi: 10.4093/dmj.2021.0331. Epub 2022 Jan 27.
2
Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study (Diabetes Metab J 2021;45:675-83).四联口服降糖药治疗血糖控制不佳的2型糖尿病的疗效与安全性：一项多中心、回顾性、观察性研究（《糖尿病与代谢杂志》2021年；45:675 - 83）
Diabetes Metab J. 2022 Jan;46(1):160-161. doi: 10.4093/dmj.2021.0309. Epub 2022 Jan 27.
3
Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study.四联口服降糖药治疗未控制 2 型糖尿病的疗效和安全性：一项多中心、回顾性、观察性研究。
Diabetes Metab J. 2021 Sep;45(5):675-683. doi: 10.4093/dmj.2020.0107. Epub 2020 Aug 12.
4
Effectiveness and Safety of Oral Quadruple Combination Therapy in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.口服四联联合疗法治疗2型糖尿病患者的有效性和安全性：一项系统评价与荟萃分析
Endocrinol Metab (Seoul). 2025 Apr;40(2):258-267. doi: 10.3803/EnM.2024.2120. Epub 2025 Jan 13.
5
Time to Reach Target Glycosylated Hemoglobin Is Associated with Long-Term Durable Glycemic Control and Risk of Diabetic Complications in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A 6-Year Observational Study (Diabetes Metab J 2021;45:368-78).达到目标糖化血红蛋白的时间与新诊断2型糖尿病患者的长期持久血糖控制及糖尿病并发症风险相关：一项6年观察性研究（《糖尿病与代谢杂志》2021年；45:368 - 78）
Diabetes Metab J. 2021 Jul;45(4):613-614. doi: 10.4093/dmj.2021.0129. Epub 2021 Jul 30.
6
Time to Reach Target Glycosylated Hemoglobin Is Associated with Long-Term Durable Glycemic Control and Risk of Diabetic Complications in Patients with Newly Diagnosed Type 2 Diabetes Mellitus: A 6-Year Observational Study (Diabetes Metab J 2021;45:368-78).达到目标糖化血红蛋白的时间与新诊断2型糖尿病患者的长期持久血糖控制及糖尿病并发症风险相关：一项6年观察性研究（《糖尿病与代谢杂志》2021年；45:368 - 78）
Diabetes Metab J. 2021 Jul;45(4):617-618. doi: 10.4093/dmj.2021.0152. Epub 2021 Jul 30.
7
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64).二甲双胍、西他列汀和恩格列净初始三联组合用于初治2型糖尿病患者的两年治疗疗效及安全性（《糖尿病与代谢杂志》2024年；48:253 - 64）
Diabetes Metab J. 2024 Sep;48(5):1005-1007. doi: 10.4093/dmj.2024.0417. Epub 2024 Sep 1.
8
Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients (Diabetes Metab J 2024;48:253-64).二甲双胍、西他列汀和恩格列净初始三联组合用于初治2型糖尿病患者的两年治疗疗效和安全性（《糖尿病代谢杂志》2024年；48:253 - 64）
Diabetes Metab J. 2024 Sep;48(5):1012-1013. doi: 10.4093/dmj.2024.0485. Epub 2024 Sep 1.
9
Effectiveness and safety of once-weekly subcutaneous semaglutide versus other glucose-lowering agents in real-world patients with type 2 diabetes: A retrospective, observational post-marketing study.在2型糖尿病真实世界患者中，每周一次皮下注射司美格鲁肽与其他降糖药物相比的有效性和安全性：一项回顾性、观察性上市后研究。
Diabetes Obes Metab. 2024 Jun;26(6):2513-2516. doi: 10.1111/dom.15552. Epub 2024 Mar 18.
10
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.胰岛素甘精胰岛素滴定上调与胰岛素德谷胰岛素/利拉鲁肽对血糖控制不佳的 2 型糖尿病患者糖化血红蛋白水平的影响：DUAL V 随机临床试验。
JAMA. 2016 Mar 1;315(9):898-907. doi: 10.1001/jama.2016.1252.
本文引用的文献
1
Efficacy and Safety of Treatment with Quadruple Oral Hypoglycemic Agents in Uncontrolled Type 2 Diabetes Mellitus: A Multi-Center, Retrospective, Observational Study.四联口服降糖药治疗未控制 2 型糖尿病的疗效和安全性：一项多中心、回顾性、观察性研究。
Diabetes Metab J. 2021 Sep;45(5):675-683. doi: 10.4093/dmj.2020.0107. Epub 2020 Aug 12.
2
Clinical Efficacy of Quadruple Oral Therapy for Type 2 Diabetes in Real-World Practice: A Retrospective Observational Study.四重口服疗法在2型糖尿病实际临床中的疗效：一项回顾性观察研究
Diabetes Ther. 2020 Sep;11(9):2029-2039. doi: 10.1007/s13300-020-00881-3. Epub 2020 Jul 21.
3
Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study.恩格列净对比达格列净在二甲双胍、格列美脲和二肽基肽酶 4 抑制剂控制不佳的 2 型糖尿病患者中的应用：一项 52 周前瞻性观察研究。
Diabetes Res Clin Pract. 2019 May;151:65-73. doi: 10.1016/j.diabres.2019.04.008. Epub 2019 Apr 4.
4
Effectiveness and safety of empagliflozin-based quadruple therapy compared with insulin glargine-based therapy in patients with inadequately controlled type 2 diabetes: An observational study in clinical practice.恩格列净为基础的四联疗法对比甘精胰岛素为基础的疗法在血糖控制不佳的 2 型糖尿病患者中的有效性和安全性：一项临床实践中的观察性研究。
Diabetes Obes Metab. 2019 Jan;21(1):173-177. doi: 10.1111/dom.13476. Epub 2018 Aug 22.
5
Dapagliflozin improves blood glucose in diabetes on triple oral hypoglycemic agents having inadequate glucose control.达格列净可改善血糖控制不佳的三联口服降糖药治疗的糖尿病患者的血糖水平。
Diabetes Res Clin Pract. 2018 Aug;142:188-194. doi: 10.1016/j.diabres.2018.05.013. Epub 2018 May 26.
6
Delay of insulin initiation in patients with type 2 diabetes mellitus inadequately controlled with oral hypoglycemic agents (analysis of patient- and physician-related factors): A prospective observational DIPP-FACTOR study in Korea.口服降糖药治疗控制不佳的2型糖尿病患者起始胰岛素治疗延迟（患者及医生相关因素分析）：韩国一项前瞻性观察性DIPP-FACTOR研究
J Diabetes Investig. 2017 May;8(3):346-353. doi: 10.1111/jdi.12581. Epub 2017 Mar 30.
7
Treatment intensification for patients with type 2 diabetes and poor glycaemic control.强化治疗改善血糖控制不佳的 2 型糖尿病患者的预后
Diabetes Obes Metab. 2016 Sep;18(9):892-8. doi: 10.1111/dom.12683. Epub 2016 Jun 14.
Zotero 插件